In the context of a global proteomic approach in PBMCs from 6 RA patients treated by the MTX/ETA combination (Population 1), we focused our attention on the abundance levels of S100A9 and S100A8 proteins that were identified as potential theranostic biomarkers among a panel of candidate proteins. This evidence concerns the gene S100A9 and rheumatoid arthritis.